• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Praxis Precision Medicines Inc (NQ: PRAX )

    42.16 +2.05 (+5.11%)
    Streaming Delayed Price Updated: 9:55 AM EDT, Jun 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 45,348
    Open 40.35
    Bid (Size) 42.04 (1)
    Ask (Size) 42.72 (4)
    Prev. Close 40.11
    Today's Range 39.67 - 42.66
    52wk Range 0.8500 - 67.21
    Shares Outstanding 44,712,538
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Jazz Dives — And Takes Praxis With It — On Essential Tremor Drug Failure
    The companies are working on treatments for essential tremor, a tricky indication. 
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga

    Performance

    YTD
    +101.72%
    +101.72%
    1 Month
    -5.83%
    -5.83%
    3 Month
    -19.56%
    -19.56%
    6 Month
    +112.29%
    +112.29%
    1 Year
    +3732.73%
    +3732.73%

    More News

    Read More
    Demystifying Praxis Precision Medicine: Insights From 7 Analyst Reviews
    Via Benzinga
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Recap: Praxis Precision Medicine Q4 Earnings
    Via Benzinga
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Praxis Precision Medicines to Participate in Upcoming Investor Conferences
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Critical Insights From Praxis Precision Medicine Analyst Ratings: What You Need To Know
    Via Benzinga
    PRAX Stock Earnings: Praxis Precision Medicine Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Praxis Precision Medicines to Participate in Upcoming April Conferences
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Praxis Precision Medicines, Inc. Announces Proposed Public Offering
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Why Praxis Precision Medicines Stock Is Trading Higher Tuesday
    Via Benzinga
    Tesla, Krispy Kreme, McCormick And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Praxis, A Top 1% Stock, Soars To Year-High After Epilepsy Treatment Scores Big
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Praxis Precision Medicines to Host PRAX-628 Program Update
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    PRAX Stock Earnings: Praxis Precision Medicine Beats EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.